NBY NovaBay Pharmaceuticals

NovaBay Pharmaceuticals to Present at Rodman & Renshaw 19th Annual Global Investment Conference

EMERYVILLE, Calif.--(BUSINESS WIRE)--

NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® lid and lash hygiene for the domestic eye care market, announces that Chief Financial Officer Jack McGovern is scheduled to present a corporate overview at the Rodman & Renshaw 19th Annual Global Investment Conference on Tuesday, September 12th, 2017, at 2:10 p.m. Eastern time (11:10 a.m. Pacific time). The conference is being held at the New York Palace Hotel in New York City.

A live webcast and replay will be available on the Investors section of the Company's website at http://novabay.com/investors/events.

About Avenova®

Avenova is NovaBay Pharmaceuticals’ main commercial focus. Data from a multicenter clinical study show that Avenova reduced bacterial load, the underlying cause of blepharitis, on ocular skin surface by more than 90%. Laboratory tests show that hypochlorous acid has potent antimicrobial activity in solution yet is non-toxic to mammalian cells and also neutralizes bacterial toxins. Avenova is marketed to optometrists and ophthalmologists throughout the U.S. by NovaBay’s direct salesforce. It is accessible from more than 90% of retail pharmacies in the U.S. through agreements with McKesson Corporation, Cardinal Health and AmerisourceBergen.

About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®

NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focusing on commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: the NEUTROX® family of products and the AGANOCIDE® compounds. The Neutrox family of products includes AVENOVA® for the eye care market, NEUTROPHASE® for wound care market, and CELLERX® for the aesthetic dermatology market. The Aganocide compounds, still under development, have target applications in the dermatology and urology markets.

Stay informed on NovaBay's progress:

Download our Mobile InvestorApp from the Apple Store or Google Play

Like us on Facebook

Follow us on Twitter

Connect with NovaBay on LinkedIn

Join us on Google+

Visit NovaBay's Website

EN
05/09/2017

Underlying

NBYNovaBay Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NovaBay Pharmaceuticals

 PRESS RELEASE
Free
NBY NovaBay Pharmac...

NovaBay Pharmaceuticals’ Avenova® Warm Eye Compress for the Relief of ...

EMERYVILLE, Calif.--(BUSINESS WIRE)-- . (NYSE American: NBY), a pharmaceutical company focusing on commercializing Avenova for the eye care market, announces the availability of its new Warm Eye Compress on and on . This new, reusable heated eye compress is designed to relieve the symptoms associated with blepharitis, dry eye disease, meibomian gland disease, styes and chalazion, and is a companion product to Avenova, NovaBay’s premier antimicrobial lid and lash spray. This press release features multimedia. View the full release here: Avenova Warm Eye Compress (Graphic: Business Wire) “Most ...

March 31, 2021 1 EN
 PRESS RELEASE
Free
NBY NovaBay Pharmac...

Ra Medical Systems to Participate in Upcoming Virtual Investment Confe...

CARLSBAD, Calif.--(BUSINESS WIRE)-- Ra Medical Systems, Inc. (NYSE American: RMED), a medical device company focusing on commercializing excimer laser systems to treat vascular and dermatological diseases, announces that management will participate in two upcoming virtual investment conferences: 33rd Annual Roth Conference being held March 15-17, 2021. Ra Medical will hold virtual investor meetings. Investors interested in arranging a meeting should contact their Roth Capital Partners sales representative or LHA Investor Relations. Roth Conference information is available . Maxim 2021 Eme...

March 11, 2021 1 EN
 PRESS RELEASE
Free
NBY NovaBay Pharmac...

NovaBay CEO Issues Letter to Stockholders

EMERYVILLE, Calif.--(BUSINESS WIRE)-- NovaBay Pharmaceuticals (NYSE American: NBY) issued the following Letter to Stockholders: To My Fellow Stockholders: NovaBay Pharmaceuticals enters 2021 focused on growing sales of our high-quality, differentiated consumer products: ®, the premier antimicrobial lid and lash spray, and , a breakthrough product that marked our entry into a new beauty category late last year. I’m excited to announce that we will soon expand consumer access to both products to brick-and-mortar retail stores. Avenova will be available at CVS stores, one of the nation’s larges...

February 8, 2021 1 EN
 PRESS RELEASE
Free
NBY NovaBay Pharmac...

NovaBay Pharmaceuticals Announces Pricing of $2.7 Million Private Plac...

NovaBay Pharmaceuticals Announces Pricing of $2.7 Million Private Placement of Preferred Stock and Accompanying Warrants to Purchase Common Stock EMERYVILLE, Calif., Aug. 09, 2019 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing Avenova for the domestic eye care market, today announced that it has entered into a securities purchase agreement with certain non-U.S. institutional accredited investors providing for the purchase and sale, in a private placement, of (i) the Company’s preferred stock automatically co...

August 9, 2019 1 EN
 PRESS RELEASE
Free
NBY NovaBay Pharmac...

NovaBay Pharmaceuticals Announces Pricing of $4.2 Million Registered D...

NovaBay Pharmaceuticals Announces Pricing of $4.2 Million Registered Direct Offering EMERYVILLE, Calif., Aug. 09, 2019 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing Avenova for the domestic eye care market, today announced that it has entered into a securities purchase agreement with certain institutional investors providing for the purchase and sale of 4,198,566 shares of common stock at a price of $1.00 per share in a registered direct offering, resulting in total gross proceeds of approximately $4.2 mill...

August 9, 2019 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch